Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow

Rhea-AI Summary

Veeva (NYSE: VEEV) announced Veeva eSource, a new SiteVault application to eliminate paper at clinical sites and streamline data flow from EHR to EDC. The solution offers direct trial data capture, EHR integration, bidirectional EDC integration, an open API, and aims to remove source data verification work. Early adopter availability is planned for second half of 2026 and requires SiteVault CTMS at the site.

News Market Reaction – VEEV

-3.67%

1 alert

-3.67% News Effect

On the day this news was published, VEEV declined 3.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $172.59 Vol: Volume 1,811,796 vs 20‑da...

normal vol

$172.59 Last Close

Volume Volume 1,811,796 vs 20‑day average 1,669,456 (relative volume 1.09). normal

Technical Price $217.99 trading below 200‑day MA at $263.47, well under 52‑week high $310.50.

Peers on Argus

VEEV is roughly flat at +0.06% while key peers like GEHC, DOCS, TEM, WAY and HQY...

VEEV is roughly flat at +0.06% while key peers like GEHC, DOCS, TEM, WAY and HQY show same‑day declines between -0.17% and -3.12%, indicating stock‑specific dynamics around this announcement.

Previous Clinical trial Reports

5 past events · Latest: Nov 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 04	Platform adoption update	Positive	+0.3%	More than 100 emerging biotechs adopting Veeva Basics platform applications.
Sep 29	Industry research report	Neutral	+0.9%	Research highlighting clinical data management inefficiencies and demand for automation.
Jun 11	MedTech platform uptake	Positive	+1.6%	Significant adoption of Veeva MedTech clinical platform across over 50 companies.
Jun 04	Oncology trial collaboration	Positive	-0.4%	Strategic collaboration with SCRI to enhance oncology clinical trials.
Apr 01	New CTMS launch	Positive	-1.6%	Announcement of SiteVault CTMS to streamline research site trial management.

Pattern Detected

Clinical‑trial–focused announcements have typically led to modest positives, but there are instances where positive site/clinical product news coincided with short‑term share declines.

Recent Company History

Recent clinical‑trial–tagged news shows Veeva expanding its role in trial operations and data quality. Since April 2025, it launched SiteVault CTMS, deepened collaborations such as with Sarah Cannon Research Institute, and reported strong MedTech and biotech adoption of its clinical platforms. Price reactions to these updates ranged from small gains to modest declines, suggesting that product and adoption milestones often produce limited but generally constructive moves around +/-1–2% rather than outsized swings.

Historical Comparison

+1.0% avg move · In the past year, VEEV issued 5 clinical‑trial–tagged updates, with an average move of +0.96%. React...

clinical trial

+1.0%

Average Historical Move clinical trial

In the past year, VEEV issued 5 clinical‑trial–tagged updates, with an average move of +0.96%. Reactions to similar site and data‑flow announcements tended to be modest rather than extreme.

Clinical‑trial news has tracked a steady build‑out of Veeva’s site and clinical ecosystem, from launching SiteVault CTMS and broader MedTech adoption to research on data inefficiencies. The new eSource application extends this progression by digitizing source capture and linking EHR, eSource, and EDC for sites.

Market Pulse Summary

This announcement highlights Veeva’s push to streamline clinical trial operations by linking eSource...

Analysis

This announcement highlights Veeva’s push to streamline clinical trial operations by linking eSource, EHR, and EDC within the SiteVault ecosystem, aiming to cut paper use and manual data entry. Prior clinical‑trial–related updates showed steady expansion of site and platform capabilities with generally modest share reactions around +/-1–2%. Key factors to monitor include early‑adopter uptake in the second half of 2026, how well the open API integrates with non‑Veeva EDCs, and feedback from research sites on workflow efficiency gains.

Key Terms

electronic health record (ehr), edc, ctms, api

4 terms

electronic health record (ehr) medical

"Electronic Health Record (EHR) Integration: Transfers relevant patient data into eSource"

A digital system that stores a patient’s medical history, test results, medications and treatment notes in one place so healthcare providers can view and update records electronically. For investors, EHRs matter because they drive how healthcare is delivered, influence costs, create recurring revenue for software providers, and carry regulatory and cybersecurity risks; think of an EHR as the digital filing cabinet or smartphone app that organizes a clinic’s entire patient chart.

edc technical

"Transfers relevant patient data into eSource, then on to EDC."

An electronic data capture (EDC) system is software used to collect, store and manage clinical trial information digitally instead of on paper. Think of it as a secure online form and filing cabinet that organizes patient visits, test results and compliance records; faster, cleaner data helps sponsors spot problems sooner, shorten development timelines and reduce regulatory risk. Investors track EDC quality because it can speed trials, cut costs and affect the credibility of trial results.

ctms technical

"Works alongside Veeva SiteVault CTMS, so that the site and patient"

A clinical trial management system is software that organizes and tracks the operational side of medical studies—handling patient enrollment, visit scheduling, data collection, budgets and regulatory paperwork. For investors, it matters because good systems can speed up development, lower costs and reduce the chance of delays or compliance problems—like project-management and filing tools that keep a complex construction project on time and within budget.

api technical

"Veeva eSource's open API enables connection to any EDC system."

An API, or Application Programming Interface, is a set of rules that allows different software programs to communicate and work together smoothly, much like a waiter translating your order into the kitchen and then bringing your meal back. For investors, APIs are important because they enable real-time access to financial data, trading systems, and other digital services, making it easier to make informed decisions quickly and efficiently.

AI-generated analysis. Not financial advice.

Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, faster

PLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva eSource, a new Veeva SiteVault application designed to significantly reduce manual clinical trial processes and increase data quality. Veeva eSource will eliminate paper at the site through a direct data capture application and streamline data through EDC integration, and EHR to EDC transfer.

"I'm excited to see Veeva eSource in action; although there are other options in use by sites, traditional eSource is still incredibly time-consuming to program, complete, and transfer data from eSource to EDC," said Alisha Garibaldi, CEO, Skylight Health Research. "A seamless flow of data from Veeva eSource to EDC will reduce errors, minimize QC processing, and allow us to spend more time where it matters – with our patients."

With Veeva eSource, clinical trial data flows from site to sponsor with less effort through:

• Electronic Health Record (EHR) Integration: Transfers relevant patient data into eSource, then on to EDC. Eliminating the duplicate data capture happening in EDC today eases the burden on sites and patients.
  
  
• Direct Trial Data Capture Application: A simple, intuitive application that allows sites to collect trial data digitally, rather than on paper. Works alongside Veeva SiteVault CTMS, so that the site and patient can have one cohesive experience for the patient's journey in a trial.
  
  
• EDC Integration: Automates the flow of patient data from eSource to Veeva EDC, reducing latency and the risk of errors. The bidirectional integration also delivers the study protocol from EDC to eSource so sites can easily create forms that align with the study design. Veeva eSource's open API enables connection to any EDC system.
  
  
• Eliminates SDV: By collecting and using source data (versus transcribed data), Veeva eSource eliminates the need for laborious sponsor work for source data verification (SDV), freeing up time for sponsor staff to spend more effectively with the site.

"For the first time, we are connecting data and processes to enable straight-through clinical data flow from site to sponsor," said Jim Reilly, president of Veeva Development Cloud. "It is a major step toward our vision to simplify, standardize, and connect clinical trials for higher efficiency and a better experience for sponsors, sites, and patients."

"Veeva eSource advances our goal of delivering significant efficiency and simplicity for clinical trial sites," said Nick Frenzer, general manager of Veeva site solutions. "By delivering eSource, we can complete the picture to provide integrated data transparency across a site to improve trials."

Veeva eSource is part of the Veeva SiteVault platform and requires SiteVault CTMS at the site to simplify and streamline the visit experience for the site and patient. Veeva eSource is planned for early adopter availability in the second half of 2026.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Deivis Mercado	Jeremy Whittaker
Veeva Systems	Veeva Systems
925-226-8821	+49-695-095-5486
deivis.mercado@veeva.com	jeremy.whittaker@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-announces-esource-application-for-research-sites-to-eliminate-paper-and-streamline-clinical-trial-data-flow-302673431.html

SOURCE Veeva Systems

FAQ

What is Veeva eSource and how will it affect clinical trial sites (VEEV)?

Veeva eSource is a digital site application that eliminates paper and duplicate entry in trials. According to Veeva, it captures trial data directly, connects EHR to EDC, and aims to reduce errors and site workload while improving data flow to sponsors.

When will Veeva eSource be available for early adopters and what are the requirements (VEEV)?

Early adopter availability is planned for the second half of 2026. According to Veeva, sites will need SiteVault CTMS to use Veeva eSource and integrate the application into the site's trial workflow and patient visits.

How does Veeva eSource integrate with EHR and EDC systems for VEEV customers?

Veeva eSource transfers relevant patient data from EHR into eSource, then on to EDC with bidirectional flow. According to Veeva, the open API enables connection to any EDC and automates protocol alignment between EDC and eSource forms.

Will Veeva eSource reduce source data verification (SDV) work for sponsors using VEEV products?

Veeva eSource is designed to eliminate SDV by using source-captured data rather than transcribed records. According to Veeva, that should free sponsor staff from laborious SDV tasks and reduce QC processing needs.

What operational benefits does Veeva claim Veeva eSource will deliver to sponsors, sites, and patients (VEEV)?

Veeva says eSource simplifies and standardizes clinical data flow to improve efficiency across trials. According to Veeva, benefits include fewer transcription errors, lower latency between site and sponsor, and a more cohesive site-patient trial experience.